Search

Reporting from: European Society of Cardiology Congress September 3-7, 2005, Stockholm In this edition: The RITA-3 trial – focussing on how to manage patients with acute coronary syndromes &#821

Andrew J Molyneux, Neurovascular Research Unit, Radcliffe Infirmary, Oxford REFERENCE: Lancet 2005;366:809-17 A trans-catheter treatment for ruptured intracranial aneurysm has proved superior to tradi

Keith Fox Keith Fox, Royal Infirmary Edinburgh The RITA-3 trial – focussing on how to manage patients with acute coronary syndromes – reported 5-year data at this year’s ESC Congress

Bruno Scheller Bruno Scheller, Universitatsklinikum des Saarlandes, Homburg Saar A future option for treating in-stent restenosis is the idea of coating a balloon with an anti-proliferative drug and i

Jean Fajadet The ESC heard the latest on the Endeavor stent, which elutes the sirolimus analogue ABT-578. Jean Fajadet from Toulouse told Audio Medica about the findings from ENDEAVOR II study of arou

David Wood Heart disease patients need to change lifestyle and not just take medicines. That’s the message in Stockholm from the EuroAction Project, which is investigating the potential of a nur

Caroline Daly The Euroheart survey has found significant differences in both diagnosis and treatment of heart disease in women as compared with men. Audio Medica asked Caroline Daly of London’s

Audio Medica talked with Roberto Ferrari , Vice President of the ESC, about the PREAMI study on the use of the ACE inhibitor perindopril in older patients who have survived acute myocardial infarction

Frans Van de Werf In the treatment of acute myocardial infarction the 24-country ASSENT-4 study seems to show an overall increase of risk if you use thrombolysis before primary PCI. Frans Van de Werf

John Cleland Cardiac resynchronisation has proved even more beneficial in severe heart failure than was proven a year ago by early results from the CARE-HF study. At the European Cardiology meeting in

Ronnie Willenheimer It could be just as good to start treatment for heart failure with a beta blocker first and subsequently use an ACE inhibitor, as the more convetional use of an ACE inhibitor first

Gilles Montalescot The STEEPLE trial randomised more than 3500 elective angioplasty patients to unfractionated heparin or either of two dose levels of enoxaparin. Gilles Montalescot presented the find